eribulin mesylate / Generic mfg. - LARVOL DELTA

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort. (PubMed, ESMO Open) - "In this China cohort, Dato-DXd demonstrated numerically improved efficacy versus ICC and a manageable safety profile, consistent with the global population, supporting Dato-DXd as a new treatment option for Chinese patients with previously treated metastatic HR+/HER2- breast cancer."

Journal • Breast Cancer • Dental Disorders • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Mucositis • Neutropenia • Oncology • Solid Tumor • Stomatitis • HER-2

Phase 1 Dose Escalation Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. (PubMed, Clin Cancer Res) - "E7389-LF was well-tolerated at 2.0 mg/m Q3W and 1.5 mg/m Q2W. Considering the toxicity profile of both regimens, the recommended dose was 2.0 mg/m Q3W. Expansion cohorts are ongoing."

Journal • P1 data • Febrile Neutropenia • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Solid Tumor • CD31 • FLT4 • ICAM1 • IFNG

E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114. (PubMed, Breast Cancer Res) - P1 | "These results highlight the antitumor activity and manageable safety profile of E7389-LF, indicating the potential of E7389-LF as a 1L treatment for patients with HER2-negative breast cancer, warranting further study."

Biomarker • Journal • P1 data • Alopecia • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Immunology • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • Triple Negative Breast Cancer • HER-2 • IFNG

Final results of a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin, and pazopanib: 2ND-STEP study, JCOG1802. (ASCO 2026) - "Funded by Japan Agency for Medical Research and Development (AMED) Clinical Trial Registration Number: jRCTs031190152 Background: The optimal second-line treatment for advanced soft tissue sarcomas (STS) after doxorubicin therapy remains unclear. This trial aimed to identify the most promising agent among trabectedin, eribulin, and pazopanib for subsequent phase III comparison against gemcitabine plus docetaxel (GD), which has traditionally been considered a standard treatment... Consistent with the primary analysis, pazopanib generally showed favorable PFS, OS, and DCR among the three agents. Based on these results, pazopanib was identified as the most appropriate candidate to be compared with GD in a phase III trial, which is currently being planned."

Clinical • Metastases • P2 data • Leiomyosarcoma • Liposarcoma • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Association of Prior Local Therapy with Outcomes Within Systemic Therapy Regimen Cohorts in Advanced Soft Tissue Sarcoma: A Retrospective Cohort Study. (PubMed, Cancers (Basel)) - " This retrospective cohort included 75 patients with recurrent or metastatic STS who contributed 155 treatment episodes: doxorubicin (n = 44), trabectedin (n = 31), pazopanib (n = 42), and eribulin (n = 38). No between-regimen differences were formally tested. These findings support individualized multidisciplinary assessment and external validation."

Journal • Retrospective data • Leiomyosarcoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. (ASCO 2026) - P3 | "Approved drugs offer modest benefit such as trabectedin (median progression-free survival [mPFS] 2.2 months [m]) or eribulin (mPFS 2.0m)...In single-arm phase 2 studies, treatment with selective CDK4 inhibitors resulted in mPFS 4.2m with palbociclib and mPFS 7.7m with abemaciclib... Abemaciclib demonstrated a statistically significant improvement in PFS vs placebo in pts with dedifferentiated liposarcoma, with an encouraging OS trend. These results support abemaciclib as a new treatment option for dedifferentiated liposarcoma."

Clinical • Late-breaking abstract • Metastases • P3 data • Liposarcoma • Sarcoma • Solid Tumor

Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC) (SABCS 2022) - "Pts were randomized 1:1 to receive SG (10 mg/kg IV on d 1 and 8, every 21 d) or TPC (eribulin, gemcitabine, capecitabine, or vinorelbine) until disease progression or unacceptable toxicity. In this TROPiCS-02 post-hoc analysis, improved efficacy with SG vs TPC was observed regardless of Trop-2 expression, and there was no clear level of Trop-2 expression at which a better treatment effect for SG was observed. These results support SG as an effective novel treatment option for patients with pretreated, endocrine- resistant HR+/HER2- mBC, and reinforce that Trop-2 testing is not required for SG treatment."

Clinical • Breast Cancer • HER2 Breast Cancer • Oncology • Triple Negative Breast Cancer • HER-2

Association of 18-Gene Expression Profile (GEP) With Clinical Outcomes in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC) Treated With Pembrolizumab (Pembro) or Chemotherapy (Chemo) in KEYNOTE-119 (ESMO-BC 2023) - P3 | "Methods Pts with centrally confirmed mTNBC, ECOG PS ≤1, and 1-2 prior systemic treatments for metastatic breast cancer were randomized 1:1 to pembro 200 mg Q3W for up to 35 cycles or TPC (capecitabine, eribulin, gemcitabine, or vinorelbine) per local guidelines. Conclusions These findings suggest a positive association between GEP and clinical outcomes in pts with mTNBC who are treated with pembro, with a more favorable treatment effect in the GEP-enriched population. Results may help inform future analyses of outcomes by biomarker status in this population."

Clinical • Clinical data • IO biomarker • Metastases • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • HRD • PD-L1

Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. (ASCO 2022) - P1 | "Selinexor with eribulin is safe with manageable toxicity profile and modest overall clinical efficacy. Durable responses and disease control were observed with metastatic TNBC. Further study is needed to examine the determinants of response to this combination."

P1 data • Anemia • Breast Cancer • Fatigue • Hematological Disorders • Inflammation • Leukopenia • Neutropenia • Oncology • Pneumonia • Sarcoma • Solid Tumor • Triple Negative Breast Cancer • XPO1

Trastuzumab deruxtecan plus pertuzumab as a substantial advancement in previously untreated patients with HER2-positive metastatic breast cancer. (PubMed, Eur Rev Med Pharmacol Sci) - "Indirect comparisons based on reconstructed patient-level data suggest that trastuzumab deruxtecan plus pertuzumab currently represents the most effective first-line strategy for HER2+MBC in terms of PFS."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors. (ASCO 2023) - P1 | "Background: BB-1701 is an antibody-drug conjugate consisting of a humanized IgG1κ monoclonal antibody and eribulin. BB-1701 was generally well tolerated up to 2.6 mg/kg dose levels and has shown promising antitumor activity in patients with HER2-overexpression solid tumors. Clinical trial information: NCT04257110."

Clinical • Metastases • P1 data • PK/PD data • Anemia • Breast Cancer • Colorectal Cancer • Dyslipidemia • Esophageal Cancer • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Disorders • Hepatology • HER2 Breast Cancer • Hypertriglyceridemia • Infectious Disease • Interstitial Lung Disease • Oncology • Ovarian Cancer • Pain • Pulmonary Disease • Respiratory Diseases • Septic Shock • Solid Tumor • CTSB • HER-2

Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. (PubMed, Int J Cancer) - "The combination therapy was manageable in terms of safety and toxicity, with a predictable safety profile. These findings suggest that lenvatinib and eribulin represent a promising treatment strategy for advanced, heavily pretreated solid tumors, warranting further exploration in larger clinical studies."

Journal • P2 data • Breast Cancer • Cardiovascular • Fatigue • Febrile Neutropenia • Hematological Disorders • Hypertension • Infectious Disease • Lung Cancer • Mucositis • Neutropenia • Oncology • Sarcoma • Septic Shock • Solid Tumor • Stomatitis • VIM

Eribulin in patients with unresectable or metastatic liposarcoma after anthracycline-containing chemotherapy: a real-world retrospective cohort study (ESMO 2026) - No abstract available

Metastases • Real-world • Real-world evidence • Retrospective data • Liposarcoma • Oncology • Sarcoma • Solid Tumor

Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study (ESMO 2022) - P3 | "Methods Pts with HR+/HER2– unresectable locally advanced or MBC and 2-4 prior chemotherapy regimens for MBC were randomized 1:1 to receive SG (10 mg/kg IV on d 1 and 8, every 21 d) or TPC (capecitabine, eribulin, vinorelbine, or gemcitabine) until unacceptable toxicity or disease progression. Conclusions Clinical benefit with SG vs TPC in HER2 IHC0 and HER2-Low HR+/HER2- MBC was consistent with that of the TROPiCS-02 ITT population. SG should be considered an effective treatment option for pts with HR+/HER2- MBC, regardless of HER2 status."

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE). (PubMed, Clin Cancer Res) - "Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity."

Journal • P2 data • Angiosarcoma • Oncology • Sarcoma • Solid Tumor

Fruquintinib plus eribulin in patients with metastatic HR+, HER2-reast cancer after progression on endocrine therapy plus CDK4/6 inhibitor: Updated results from a phase II study (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • HER-2

Tbcrc 058: a randomized phase 2 study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (nct06099769) (SABCS 2025) - P2 | " This is a randomized phase II trial; 201 patients (pts) will be randomized in a 1:1:1 fashion to enza, enza plus mif, or TPC (carboplatin, paclitaxel, eribulin, or capecitabine). Pts must have normal organ function and no history of brain mets. As of 7/9/2025, 19 of 201 pts have begun protocol-specified tx."

Clinical • IO biomarker • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • AR • CTCs • ER • HER-2 • PGR

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers (clinicaltrials.gov) - P1/2 | N=138 | Not yet recruiting | Sponsor: Advenchen Pharmaceuticals, LLC.

dMMR • MSI-H • New P1/2 trial • Breast Cancer • Endometrial Cancer • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • MSI

Safety of eribulin: A real-world study based on a pharmacovigilance database. (PubMed, PLoS One) - "Critically, serious unexpected AEs not consistently referenced in drug inserts were identified, such as pleural effusion, respiratory failure, and cardiac failure. Clinical use of eribulin requires great attention to blood and lymphatic adverse events, as well as enhanced monitoring and reporting of adverse events not mentioned in the insert to prevent serious AEs."

Adverse events • Journal • Real-world evidence • Breast Cancer • Cardiovascular • Congestive Heart Failure • Febrile Neutropenia • Heart Failure • Hematological Disorders • Leukopenia • Neutropenia • Oncology • Respiratory Diseases • Solid Tumor

Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the Phase 3 ASCENT study (ESMO-BC 2022) - P3 | "This ASCENT post hoc subgroup analysis evaluates SG efficacy in HER2 IHC0 and HER2-Low mTNBC.Methods Patients (pts) with mTNBC refractory/relapsing after ≥2 prior chemotherapies (≥1 in the metastatic setting) were randomized 1:1 to receive SG (10 mg/kg IV on d 1 and 8, every 21 d) or TPC (capecitabine, eribulin, vinorelbine, or gemcitabine) until unacceptable toxicity/progression. HER2-Low had numerically better outcomes vs HER2 ICH0 in both the SG and TPC arms.Conclusions Clinical benefit with SG in HER2 IHC0 and HER2-Low mTNBC was consistent with that of the ASCENT ITT population, regardless of HER2 status. SG should be considered an effective treatment option for pts with mTNBC eligible for 2L or later therapy."

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

Efficacy, safety and circulating tumor cell dynamics in patients treated with Eribulin for HER2-negative advanced breast cancer - results from the phase II DETECT IVb trial. (PubMed, Breast Cancer Res Treat) - P2 | "In this trial, we could confirm eribulin as an effective treatment option in high-risk HER2-negative MBC. CTCs proved their role as a prognostic marker and our results support the potential role of CTC dynamics as an early biomarker of treatment response to eribulin."

Biomarker • Circulating tumor cells • Journal • P2 data • Breast Cancer • Fatigue • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Leukopenia • Neutropenia • Oncology • Solid Tumor • CTCs • HER-2

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial. (PubMed, J Clin Oncol) - P3 | "The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC."

Head-to-Head • Journal • P3 data • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Neutropenia • Oncology • Solid Tumor • HER-2

Eribulin After Antibody–Drug Conjugate Treatment in Metastatic Breast Cancer: A Real-World Multicenter Retrospective Study (ESMO 2026) - No abstract available

ADC • Metastases • Real-world • Real-world evidence • Retrospective data • Breast Cancer • Oncology • Solid Tumor

Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. (PubMed, Br J Cancer) - "Efficacy of eribulin in patients with leiomyosarcoma was comparable to that of dacarbazine. Both agents had manageable safety profiles."

Clinical • Journal • P3 data • Leiomyosarcoma • Oncology • Sarcoma • Solid Tumor • Uterine Leiomyoma

First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial (ESMO 2025) - P1, P3 | "Methods Adult pts with previously untreated locally recurrent inoperable or mTNBC, for whom immunotherapy was not an option, were randomised 1:1 to Dato-DXd (6 mg/kg IV Q3W) or investigator's choice of chemotherapy (ICC; [nab]-paclitaxel/ capecitabine/ eribulin mesylate/ carboplatin). The Dato-DXd safety profile was manageable. Results support Dato-DXd as the new 1L standard of care."

Clinical • Late-breaking abstract • Metastases • P3 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PD-L1